Compare Cincinnati Financial Corporation (CINF) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Ginkgo Bioworks Holdings Inc — how do they compare? Cincinnati Financial Corporation trades at $176.18 (market cap $27.85B), while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: Cincinnati Financial Corporation is far larger — about 47.2× Ginkgo Bioworks Holdings Inc's market cap, and Cincinnati Financial Corporation pays a 2.09% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| CINF | DNA | |
|---|---|---|
Market Cap | $27.85B | $590.53M |
Sector | Financials | Health |
52-Week High | $192.03 | $16.14 |
52-Week Low | $145.80 | $5.48 |
Enterprise Value | $27.52B | $627.78M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $182.67, up 1.89% with strong technical momentum near recent highs. The stock shows solid fundamentals with a P/E of 10.44, ROE of 18.73%, and consistent earnings beats in recent quarters. Recent news highlights the company's 65-year dividend streak and upcoming Q2 2026 earnings release on July 27, 2026. Operating cash flow improved to $3.11B in 2025, supporting financial stability.
CINF presents a balanced investment case with attractive valuation metrics and strong profitability, though catastrophe losses and claims costs remain key risks. Analyst consensus suggests moderate upside to the $188.67 price target. The stock's technical positioning near resistance at $184 requires monitoring of earnings performance for continued momentum.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
